Humanized and variant TGF-β3 specific antibodies and methods and uses thereof

An isolated antibody or antigen-binding fragment thereof which recognizes human and mouse transforming growth factor beta 3 (TGF-β3), which neutralizes activity of TGF-β3, and which does not recognize or bind human or mouse TGF-β1 or TGF-β2, wherein the antibody or fragment comprises a heavy chain variable region sequence comprising a CDR1 sequence SSWIH (SEQ ID NO:1), a CDR2 sequence RIYPGDGDTDYSEKFQ (SEQ ID NO:34), and a CDR3 sequence RMITTQAALDY (SEQ ID NO:

• 35) and a light chain variable region sequence comprising a CDR1 sequence KASQSVINAVA (SEQ ID NO:4), a CDR2 sequence YASNRYT (SEQ ID NO:
• 5), and a CDR3 sequence QQDYSSPY (SEQ ID NO:33);
• and wherein the antibody or fragment comprises the heavy chain variable region sequence:
• (a) LCR1901_VH_1G10m (SEQ ID NO:18) or variants thereof having at least 90% amino acid identity to the sequence LCR1901_VH_1G10m (SEQ ID NO:18), wherein said variants retain TGF-β3 reactivity and neutralization;
• (b) LCR1901_VH_1G10m_03 (K) (SEQ ID NO:19) or variants thereof having at least 90% amino acid identity to the sequence LCR1901_VH_1G10m_03 (K) (SEQ ID NO:19), wherein said variants retain TGF-β3 reactivity and neutralization;
• or
• (c) LCR1901_VH_1G10m_02 (J) (SEQ ID NO:36) or variants thereof having at least 90% amino acid identity to the sequence LCR1901_VH_1G10m_02 (J) (SEQ ID NO:36), wherein said variants retain TGF-β3 reactivity and neutralization;
• and the light chain variable region sequence:
• (d) LCR1901_VK_GLv1_03 (F) (SEQ ID NO:22) or variants thereof having at least 90% amino acid identity to the sequence LCR1901_VK_GLv1_03 (F) (SEQ ID NO:22), wherein said variants retain TGF-β3 reactivity and neutralization;
• or
• (e) LCR1901_VK_GLv1_05 (H) (SEQ ID NO:23) or variants thereof having at least 90% amino acid identity to the sequence LCR1901_VK_GLv1_05 (H) (SEQ ID NO:23), wherein said variants retain TGF-β3 reactivity and neutralization.